Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.

ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating ...

Ivonescimab demonstrated superior progression-free survival compared to Keytruda, positioning it as a potential leader ...

Investorideas ( ), a go-to investing platform, releases the second of a two-part series looking at news and developments for the <a target=_blank ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

Bicara's lead drug, ficerafusp alfa, is currently in an early-stage study in the U.S. to treat a type of head and neck cancer in combination with Merck's Keytruda. BOSTON, Sept. 12, 2024 (GLOBE ...

Key Takeaways U.S. equities rallied back from last week's selloff at midday as investors put more money into blue chip stocks ...